Semaglutide initiates Phase III clinical trial of NASH in China
On July 27, 2021, Novo Nordisk registered the Phase III clinical trial of Semaglutide in the treatment of non-alcoholic steatohepatitis (NASH) on the drug clinical trial registration and information disclosure platform website.
This international multi-center Phase III clinical program enrolled 1285 patients with NASH, including 1,200 from abroad and 85 from China. A total of 399 clinical centers around the world participated, including 24 in China (including 4 in Taiwan).
Semaglutide has been approved by the FDA for the treatment of type 2 diabetes and obesity, Alzheimer's disease (3700 cases of phase III clinical), NASH (1285 cases of phase III clinical), cardiovascular (CVD), chronic kidney disease (CKD), etc. Many important indications are under active development, and organs such as the brain, liver, heart, and kidney will all benefit from semaglutide.
In 2020, the sales of semaglutide reached 3.51 billion U.S. dollars, which is still in rapid growth, and new indications will further increase sales expectations.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
Chemical Weight Loss Retatrutide / Ly-3437943 CAS 2381089-83-2 Vial 10mg 20mg 30mg Reta Peptide
$138.27/UNIT FOB
2026-07-21
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
A Faster Route to Diabetes Drug Chemistry
-
Study Finds Semaglutide Lower Suicide Ideation Risk Compared to Other Diabetes and Obesity Medications
-
Are GLP-1 Receptor Agonists Linked to Hair Loss and Suicidal Thoughts?
-
Can New Entrants Succeed in the Competitive GLP-1 Drug Market?
-
'Weight loss needle' is coming to China soon! Why is Semaglutide the best GLP-1 student?
-
$60 billion market size! Market analysis of diabetes therapeutics
-
Cure diabetes and obesity with printed materials? Novo Nordisk Introduces Cell Therapy for $2.6 billion
-
The different paths of Chinese and foreign diabetes giants: double males and double bears
-
Semaglutide once a week for the treatment of adolescent obesity Phase III results appear in the New England Journal of Medicine: significantly reduce BMI
-
Semaglutide: Another phenomenon-level new drug, breaking one billion in 'seconds', and the 'weight loss' market is basically out of stock
Recommend Reading
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
Lilly Eyes Fast-Track Approval for Oral Weight-Loss Drug in U.S.
-
Merck and Eisai Halt Late-Stage Trial for Liver Cancer Therapy
-
U.S. Health Chief Says No Evidence Linking Tylenol to Autism
-
Pharma’s Tightrope in 2026: Safety, Competition and the Future of Obesity Treatment Innovation
-
Covestro Minority Shareholder Squeeze-Out Price Set at €59.46 per Share
-
EFSA Approves Cellulase from GM Aspergillus Niger with Low Allergy Risk
-
Methanol Market Trends in China
-
China’s EVA Market to Experience Volatile Decline in 2025, with Supply Intensifying in 2026 and Demand Remaining Stable but Weak
-
Domestic SBR Market Shows Strong Unilateral Increase